Ofloxacin + Metronidazole Suspension

This proprietary multi-salt formulation is classified as a synergistic Fluoroquinolone and Nitroimidazole combination. It is the absolute gold standard in primary care for the empiric treatment of acute pediatric diarrhea, dysentery, and mixed gastrointestinal infections.

Because both molecules possess inherently terrible organoleptic properties (metallic and profoundly bitter tastes), formulating them into a stable Suspensions format requires immense pharmaceutical expertise. By utilizing an advanced liquid dispersion matrix, complexing agents, and premium flavor engineering, Saar Biotech ensures that the suspension is highly palatable without compromising the rapid dissolution and bioavailability required to arrest severe fluid loss in pediatric patients.

The clinical success of pediatric diarrhea treatment hinges entirely on the child’s willingness to swallow and retain the medication without vomiting. Saar Biotech operates a dedicated, state-of-the-art liquid manufacturing facility located in the pharmaceutical hub of Baddi, Himachal Pradesh.

Our specialized manufacturing lines utilize high-shear homogenization to drastically reduce the particle size of both Ofloxacin and Metronidazole (often utilizing the benzoate salt for improved taste profile). We incorporate specialized cyclodextrin-based taste-masking complexes and thixotropic polymers to create a suspension that completely shields the bitter receptors on the tongue while remaining perfectly deflocculated on the shelf. Our rigid Quality Control (QC) protocols rigorously test every batch for exact API concentration, pH stability, and absolute microbial purity, making us the trusted third-party manufacturing partner for elite pediatric brands.

The combination of Ofloxacin and Metronidazole is highly prescribed across pediatric populations for the aggressive eradication of complex, mixed infections of the gastrointestinal tract and beyond.

• Acute Diarrhea & Dysentery: The primary indication. Highly effective against mixed infections caused by aerobic bacteria (like E. coli, Salmonella, Shigella) and anaerobic protozoa (like Giardia lamblia, Entamoeba histolytica).
• Amoebiasis & Giardiasis: Provides rapid eradication of both the trophozoite and cystic forms of invasive intestinal parasites.
• Intra-abdominal Infections: Utilized as step-down oral therapy for severe pelvic inflammatory disease, peritonitis, and intra-abdominal abscesses following initial intravenous intervention.
• Dental & Periodontal Infections: Often prescribed for severe acute necrotizing ulcerative gingivitis (ANUG) and complex dental abscesses where mixed aerobic-anaerobic flora are implicated.

Synergistic Dual-Action Mechanism

The phenomenal clinical speed of this suspension is driven by the fact that both APIs attack the pathogen’s DNA structure through entirely different, synergistic pathways, leaving no avenue for microbial escape:

1. Ofloxacin (The DNA Gyrase Inhibitor): A second-generation fluoroquinolone. It exerts a rapid bactericidal effect by penetrating the bacterial cell and selectively binding to DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are critical for the unwinding, supercoiling, and replication of bacterial DNA. By inhibiting them, Ofloxacin causes catastrophic double-strand DNA breaks, leading to immediate bacterial cell death, particularly in Gram-negative enteric pathogens.
2. Metronidazole (The DNA Strand Breaker): A nitroimidazole derivative. It acts as a highly selective prodrug that is only activated within anaerobic bacteria and sensitive protozoa. Once inside the anaerobic cell, the nitro group of Metronidazole is chemically reduced by the organism’s own ferredoxin system. This reduction produces highly reactive, short-lived cytotoxic intermediates that covalently bind to the pathogen’s DNA, causing massive strand breakage, loss of helical structure, and rapid cell death.

Manufacturing Integrity

Metronidazole is notoriously susceptible to photodegradation, turning a dark, unappealing brown when exposed to light. Saar Biotech overcomes this by strictly utilizing amber-colored, UV-blocking primary packaging. Ofloxacin, conversely, can form insoluble complexes with certain divalent cations if the buffer system is incorrect. We manufacture the suspension under highly controlled pH parameters (typically pH 4.5 to 5.5) utilizing specific citrate buffering systems to ensure both molecules remain completely stable, fully un-complexed, and maximally bioavailable upon entering the acidic environment of the stomach.

Absorption & Distribution

Following oral administration, both drugs exhibit excellent and rapid pharmacokinetic profiles, which is crucial for stopping acute diarrhea:

• Ofloxacin: Almost completely absorbed from the upper gastrointestinal tract, reaching peak plasma concentrations within 1 to 2 hours. It exhibits widespread tissue penetration, including high concentrations in the intestinal mucosa, bile, and blister fluid. It is primarily excreted unchanged by the kidneys.
• Metronidazole: Also rapidly and completely absorbed, with peak concentrations reached within 1 to 2 hours. It is widely distributed to almost all body tissues and fluids, including the cerebrospinal fluid (CSF), saliva, and seminal fluid. It undergoes hepatic metabolism and is primarily excreted in the urine.

Commercial Viability

For our B2B partners, the Ofloxacin + Metronidazole combination represents one of the highest-volume pediatric products in the entire Indian pharmaceutical market. It is the absolute first-line prescription during monsoon seasons and in areas with endemic waterborne pathogens. The massive prescription volume guarantees rapid inventory turnover. Marketing companies can capitalize on the unique, broad-spectrum “Aerobic + Anaerobic” coverage. Furthermore, our highly stable, perfectly taste-masked formulation ensures tremendous brand loyalty among pediatricians, making it an incredibly lucrative, high-margin addition to any pediatric or gastrointestinal portfolio.

Saar Biotech provides complete, end-to-end third-party manufacturing and contract packaging solutions for Ofloxacin and Metronidazole Suspensions, tailored to exact B2B specifications.

• Standardized Strength Formulation: Typically formulated as Ofloxacin 50mg + Metronidazole (as Benzoate) 100mg per 5ml, or the “Forte/DS” variant of 100mg/200mg per 5ml, to ensure accurate weight-based dosing for different pediatric age groups.
• Packaging Customizability: We provide 30ml and 60ml capacities utilizing high-grade amber PET bottles (to prevent photodegradation) equipped with child-resistant caps (CRC) and highly accurate measuring cups.
• Flavor Engineering: Recognizing that palatability is the single biggest factor in pediatric compliance for this specific bitter combination, we offer a vast library of heavy, masking flavor profiles, including Mango, Pineapple, and Mixed Fruit, often combined with a sucrose-sorbitol base for optimal sweetness.
• Regulatory Support: Our internal compliance team assists with CDSCO/DCGI documentation, Legal Metrology compliance for carton artworks, and the generation of comprehensive Certificates of Analysis (COA) for every dispatched batch.

To preserve the clinical efficacy and physical stability of the formulation, the suspension should be stored in a cool, dry environment, strictly below 30°C. It must be vehemently protected from direct sunlight, which will rapidly degrade the Metronidazole component. Do not freeze the suspension, as this will permanently alter the rheological properties of the suspending agents and cause the APIs to precipitate. Patients must be instructed to shake the bottle vigorously before every use to ensure complete homogenization of the dose. It is generally recommended to take the medication exactly as prescribed for the full course, even if symptoms (like diarrhea) resolve after the first few doses, to prevent the emergence of fluoroquinolone resistance.

Saar Biotech’s commitment to pharmaceutical excellence is absolute. Every batch of this complex dual-suspension is subjected to a rigid battery of analytical tests within our GLP-certified laboratories prior to release.

• Simultaneous HPLC Assay: Advanced High-Performance Liquid Chromatography (HPLC) is utilized for the simultaneous, precise quantification of both Ofloxacin and Metronidazole, ensuring the concentrations are strictly within the 90.0% to 110.0% range of the labeled amount.
• Dissolution Profiling: We constantly monitor the suspension to guarantee optimal dissolution parameters in simulated gastric fluid.
• Specific Gravity & Viscosity: Tested to guarantee the physical consistency and accurate pourability of the liquid.
• Microbial Limit Testing (MLT): Comprehensive screening confirms the absolute absence of pathogenic microorganisms, ensuring total safety for pediatric patients already suffering from gastrointestinal distress.

While highly effective, the combination of Ofloxacin and Metronidazole requires professional discretion due to its potent systemic action. The most common adverse events are mild gastrointestinal disturbances (nausea, vomiting, metallic taste in the mouth) and transient dizziness.

However, several critical precautions exist. Fluoroquinolones (like Ofloxacin) have been associated with an increased risk of tendinopathy and tendon rupture, though this is exceedingly rare in pediatric populations. It should be used with extreme caution in patients with a known history of seizure disorders, as fluoroquinolones can lower the seizure threshold. Metronidazole has a well-documented “disulfiram-like” reaction when combined with alcohol (causing severe nausea and flushing), though this is irrelevant in pediatric use. It must be used with caution in patients with severe hepatic impairment, as Metronidazole relies on liver metabolism. It is contraindicated in patients with a known hypersensitivity to fluoroquinolones or nitroimidazole derivatives.

For third-party manufacturing enquiries, private-label contracts, or to request pricing and packaging options for Ofloxacin and Metronidazole Oral Suspension, please use the B2B enquiry form below.